Scribe Therapeutics surged in its market debut, with shares trading up nearly 48.6% in afternoon activity on the first day of public trading. The stock opened at $25 and climbed to an intraday peak of $25.49 after the company set the price for its upsized initial public offering at $15 per share - the top of the marketed $13 to $15 range - the prior evening. The offering generated $128.7 million in gross proceeds.
The first-day strength reflected heavy institutional validation. Sanofi participated in a concurrent private placement, buying 500,000 shares at the IPO price. Eli Lilly, which held about 12.4% of Scribe before the offering, signaled plans to purchase additional shares at the IPO price to maintain an approximate 11% stake. That combination of strategic co-investment and anchor interest helped concentrate demand behind the deal.
Scribe’s founding team includes Nobel Prize-winning chemist Jennifer Doudna, whose role in establishing CRISPR genome editing is widely recognized. The company markets a proprietary approach centered on epigenetic silencing to modulate gene expression without permanently cleaving DNA. Market participants viewed that safety profile as a differentiator from competitors that use nuclease-based editing or base-editing technologies, such as Intellia Therapeutics, Beam Therapeutics, and Prime Medicine, all of which rely on more permanent DNA-cutting or base-editing methods.
Investor appetite was concentrated around Scribe’s cardiometabolic pipeline, particularly the lead program STX-1150, which targets the PCSK9 gene to lower LDL cholesterol. The company also benefits from more than $2 billion in total collaboration commitments from Sanofi and Eli Lilly, a sum that surfaced in market commentary as an important backstop for the programs and commercial potential.
Market conditions on the debut day provided little broader support. The Nasdaq composite declined 0.6% and the S&P 500 was essentially unchanged, indicating that Scribe’s stock movement was driven primarily by company-specific IPO mechanics rather than a favorable sector rally. Underwriters reported the offering was oversubscribed many times over the available allocation, a classic sign of concentrated anchor and institutional conviction.
In short, a combination of a Nobel-affiliated founding team, oversubscribed institutional demand, direct co-investment by major pharmaceutical partners at the IPO price, and a gene-regulation platform positioned as potentially safer than nuclease-based editing produced a pronounced first-day increase in Scribe’s shares. The stock closed the early trading session substantially above its IPO price even as broader tech and market indexes retreated.